Browse hierarchy: [Microbiology (MI)](/submissions/MI) → [Subpart D — Serological Reagents](/submissions/MI/subpart-d%E2%80%94serological-reagents) → [21 CFR 866.3967](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3967) → SBT — Device To Detect Microbial Colonization Directly From Clinical Specimens.

# SBT · Device To Detect Microbial Colonization Directly From Clinical Specimens.

_Microbiology · 21 CFR 866.3967 · Class 2_

**Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/SBT

## Overview

- **Product Code:** SBT
- **Device Name:** Device To Detect Microbial Colonization Directly From Clinical Specimens.
- **Regulation:** [21 CFR 866.3967](/submissions/MI/subpart-d%E2%80%94serological-reagents/866.3967)
- **Device Class:** 2
- **Review Panel:** [Microbiology](/submissions/MI)

## Identification

The Simplexa C. auris RT-PCR system is a real-time polymerase chain reaction (RT-PCR) assay intended for use on the LIAISON MDX instrument for the direct in vitro qualitative detection of Candida auris DNA from a composite swab of bilateral axilla/groin from patients suspected of C. auris colonization. The system consists of the Simplexa C. auris Direct (assay kit), Simplexa C. auris Positive Control Pack, and Simplexa C. auris Sample Prep Kit.

## Classification Rationale

Class II (special controls). The device is classified under 21 CFR 866.3967 - Device to detect microbial colonization directly from clinical specimens.

## Special Controls

The De Novo request is granted and the device is classified under the following and subject to the special controls identified in the letter granting the De Novo request:

## Recent Cleared Devices (1 of 1)

| Record | Device Name | Applicant | Decision Date | Decision |
| --- | --- | --- | --- | --- |
| [DEN230092](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/SBT/DEN230092.md) | Simplexa C. auris Direct, Simplexa C. auris Positive Control Pack, Simplexa C. auris Sample Prep Kit (MOL3950, MOL3960, MOL5390) | Diasorin Molecular, LLC | Jul 15, 2024 | DENG |

## Top Applicants

- Diasorin Molecular, LLC — 1 clearance

---

**Source:** [https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/SBT](https://fda.innolitics.com/submissions/MI/subpart-d%E2%80%94serological-reagents/SBT)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com